Novanta (NOVT) reported second-quarter 2026 GAAP revenue of $265.8 million, up 10.3% from the prior year. GAAP net income was $12.5 million, compared with $4.5 million a year earlier, and GAAP diluted EPS was $0.30, compared with $0.12.
The company issued third-quarter GAAP revenue guidance of $300 million to $304 million and full-year 2026 GAAP revenue guidance of $1.13 billion to $1.14 billion. Novanta said its guidance incorporates the expected contribution from the Riverpoint Medical acquisition.
- Second-quarter GAAP revenue was $265.8 million, up 10.3% year over year.
- GAAP net income was $12.5 million, versus $4.5 million in the prior year.
- GAAP diluted EPS was $0.30, compared with $0.12 a year earlier.
- Adjusted EBITDA was $60.7 million, up 16.4% year over year.
- Operating cash flow was $64.9 million, compared with $15.1 million in the prior year.
- Novanta expects third-quarter 2026 GAAP revenue of $300 million to $304 million.
- Full-year 2026 GAAP revenue is expected to be $1.13 billion to $1.14 billion.
$NOVT Insider Trading Activity
$NOVT insiders have traded $NOVT stock on the open market 34 times in the past 6 months. Of those trades, 0 have been purchases and 34 have been sales.
Here’s a breakdown of recent trading of $NOVT stock by insiders over the last 6 months:
- MATTHIJS GLASTRA (Chief Executive Officer) has made 0 purchases and 27 sales selling 47,500 shares for an estimated $6,956,568.
- ROBERT BUCKLEY (Chief Financial Officer) has made 0 purchases and 7 sales selling 11,380 shares for an estimated $1,363,118.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$NOVT Hedge Fund Activity
We have seen 189 institutional investors add shares of $NOVT stock to their portfolio, and 125 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,175,998 shares (+193.3%) to their portfolio in Q1 2026, for an estimated $138,897,123
- SCULPTOR CAPITAL LP removed 430,838 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $50,886,276
- ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC added 377,232 shares (+27.0%) to their portfolio in Q1 2026, for an estimated $44,554,871
- WASATCH ADVISORS LP removed 236,653 shares (-23.7%) from their portfolio in Q2 2026, for an estimated $38,394,582
- CONESTOGA CAPITAL ADVISORS, LLC removed 231,852 shares (-16.0%) from their portfolio in Q2 2026, for an estimated $37,615,668
- POINT72 ASSET MANAGEMENT, L.P. removed 197,569 shares (-64.6%) from their portfolio in Q1 2026, for an estimated $23,334,874
- MARSHALL WACE, LLP added 176,329 shares (+2389.9%) to their portfolio in Q1 2026, for an estimated $20,826,218
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$NOVT Congressional Stock Trading
Members of Congress have traded $NOVT stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NOVT stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 05/18.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
